Heritage Family Offices LLP Lowers Stock Position in Eli Lilly and Company $LLY

Heritage Family Offices LLP reduced its position in Eli Lilly and Company (NYSE:LLY) by 38.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,317 shares of the company’s stock after selling 821 shares during the period. Heritage Family Offices LLP’s holdings in Eli Lilly and Company were worth $1,005,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lbmc Investment Advisors LLC grew its position in Eli Lilly and Company by 92.8% during the third quarter. Lbmc Investment Advisors LLC now owns 3,470 shares of the company’s stock valued at $2,648,000 after acquiring an additional 1,670 shares during the period. Woodstock Corp lifted its stake in shares of Eli Lilly and Company by 18.0% in the 3rd quarter. Woodstock Corp now owns 11,972 shares of the company’s stock valued at $9,135,000 after purchasing an additional 1,825 shares in the last quarter. StrongBox Wealth LLC lifted its stake in shares of Eli Lilly and Company by 3.3% in the 3rd quarter. StrongBox Wealth LLC now owns 2,052 shares of the company’s stock valued at $1,566,000 after purchasing an additional 66 shares in the last quarter. Ransom Advisory Ltd grew its holdings in shares of Eli Lilly and Company by 112.9% during the 3rd quarter. Ransom Advisory Ltd now owns 2,451 shares of the company’s stock worth $1,870,000 after purchasing an additional 1,300 shares during the period. Finally, Family Legacy Financial Solutions LLC increased its position in Eli Lilly and Company by 2.2% during the 3rd quarter. Family Legacy Financial Solutions LLC now owns 8,783 shares of the company’s stock worth $6,701,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,056.57 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market capitalization of $998.86 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37. The firm’s fifty day moving average price is $956.00 and its 200 day moving average price is $828.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a report on Thursday. Finally, Bank of America reduced their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,141.73.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.